Kohrt, L., Gladbach, Y. S., Ernst, M., Hamed, M., Roolf, C., Sender, S., . . . Murua Escobar, H. (2020). Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines. Cancer cell international, 20, . https://doi.org/10.1186/s12935-020-01431-4
Chicago-Zitierstil (17. Ausg.)Kohrt, Lisa-Madeleine, et al. "Combination of the PI3K Inhibitor Idelalisib with the Conventional Cytostatics Cytarabine and Dexamethasone Leads to Changes in Pathway Activation That Induce Anti-proliferative Effects in B Lymphoblastic Leukaemia Cell Lines." Cancer Cell International 20 (2020). https://doi.org/10.1186/s12935-020-01431-4.
MLA-Zitierstil (9. Ausg.)Kohrt, Lisa-Madeleine, et al. "Combination of the PI3K Inhibitor Idelalisib with the Conventional Cytostatics Cytarabine and Dexamethasone Leads to Changes in Pathway Activation That Induce Anti-proliferative Effects in B Lymphoblastic Leukaemia Cell Lines." Cancer Cell International, vol. 20, 2020, https://doi.org/10.1186/s12935-020-01431-4.